Articles  |   October 2019
SEE Question
Article Information
Cardiovascular Anesthesia / Coagulation and Transfusion / Education / CPD / Quality Improvement / Articles
Articles   |   October 2019
SEE Question
ASA Monitor 10 2019, Vol.83, 60-61.
ASA Monitor 10 2019, Vol.83, 60-61.
You have been asked to standardize the use of tranexamic acid (TXA) in patients undergoing elective hip and knee arthroplasty at your hospital. Based on new multidisciplinary guidelines for the use of TXA in patients undergoing primary joint arthroplasty, which of the following recommendations is most appropriate?
TXA is a lysine analog that inhibits fibrinolysis by blocking the binding of plasminogen to fibrin. By reducing the ability of the plasminogen-plasmin complex to break down fibrin clots, the fibrin is stabilized and therefore favors clot formation and the reduction of bleeding. It is about 10 times more potent than aminocaproic acid, which acts in a similar fashion.
0 Comments
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Name
Affiliation & Institution
I have a potential conflict of interest
Comment Title
Comment


This feature is available to Subscribers Only
ASA Member Login or Create an Account ×